BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 21477265)

  • 1. A single-nucleotide polymorphism in the TP53 and MDM-2 gene modifies breast cancer risk in an ethnic Arab population.
    Alshatwi AA; Hasan TN; Shafi G; Alsaif MA; Al-Hazzani AA; Alsaif AA
    Fundam Clin Pharmacol; 2012 Jun; 26(3):438-43. PubMed ID: 21477265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.
    Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D
    Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population.
    Xiao M; Zhang L; Zhu X; Huang J; Jiang H; Hu S; Liu Y
    BMC Cancer; 2010 Apr; 10():147. PubMed ID: 20398418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Association of murine double minute 2 and P53 polymorphisms with breast cancer susceptibility].
    Wang ML; Xu YX; Qian J; Wang FH
    Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Feb; 47(2):124-8. PubMed ID: 23719102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
    Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
    Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis.
    Peng Q; Lao X; Chen Z; Lai H; Deng Y; Wang J; Mo C; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S
    PLoS One; 2013; 8(12):e82773. PubMed ID: 24376578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study.
    Abderrahmane R; Louhibi L; Moghtit FZ; Boubekeur A; Benseddik K; Boudjema A; Benrrahal F; Aberkane M; Fodil M; Saidi-Mehtar N
    Pathol Oncol Res; 2015 Jul; 21(3):629-35. PubMed ID: 25537146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variations in MDM2 and P53 genes confer risk for adult acute lymphoblastic leukemia in a Chinese population.
    Chen J; Zhu B; Chen J; Li Y
    DNA Cell Biol; 2013 Jul; 32(7):414-9. PubMed ID: 23745682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Genetic polymorphism in MDM2 is associated with susceptibility to colorectal cancer in a Chinese population].
    Liu JN; Zhang XM; Guo YL; Sun T; Lin DX; Wen T
    Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):335-8. PubMed ID: 18953830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma.
    Hong Y; Miao X; Zhang X; Ding F; Luo A; Guo Y; Tan W; Liu Z; Lin D
    Cancer Res; 2005 Oct; 65(20):9582-7. PubMed ID: 16230424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
    Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
    Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
    van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
    Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association of polymorphic markers Arg399Gln of XRCC1 gene, Arg72Pro of TP53 gene and T309G of MDM2 gene with breast cancer in Kyrgyz females.
    Isakova J; Talaibekova E; Aldasheva N; Vinnikov D; Aldashev A
    BMC Cancer; 2017 Nov; 17(1):758. PubMed ID: 29132330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDM2 and TP53 Polymorphisms as Predictive Markers for Head and Neck Cancer in Northeast Indian Population: Effect of Gene-Gene and Gene-Environment Interactions.
    Bhowmik A; Das S; Bhattacharjee A; Choudhury B; Naiding M; Deka S; Ghosh SK; Choudhury Y
    Asian Pac J Cancer Prev; 2015; 16(14):5767-72. PubMed ID: 26320449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.
    Hori Y; Miyabe K; Yoshida M; Nakazawa T; Hayashi K; Naitoh I; Shimizu S; Kondo H; Nishi Y; Umemura S; Kato A; Ohara H; Inagaki H; Joh T
    PLoS One; 2015; 10(3):e0118829. PubMed ID: 25734904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in Singapore.
    Koh WP; Van Den Berg D; Jin A; Wang R; Yuan JM; Yu MC
    Breast Cancer Res Treat; 2011 Dec; 130(3):1011-9. PubMed ID: 21833626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.
    Macedo GS; Vieira IA; Vianna FSL; Alemar B; Giacomazzi J; Brandalize APC; Caleffi M; Volc SM; de Campos Reis Galvão H; Palmero EI; Achatz MI; Ashton-Prolla P
    Fam Cancer; 2018 Apr; 17(2):269-274. PubMed ID: 28756477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the MDM2 promoter polymorphism (-309T>G) in acute myeloid leukemia development.
    Cingeetham A; Vuree S; Jiwatani S; Kagita S; Dunna NR; Meka PB; Gorre M; Annamaneni S; Digumarti R; Sinha S; Satti V
    Asian Pac J Cancer Prev; 2015; 16(7):2707-12. PubMed ID: 25854351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.
    Okishiro M; Kim SJ; Tsunashima R; Nakayama T; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
    Breast Cancer Res Treat; 2012 Apr; 132(3):947-53. PubMed ID: 21706156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.